Nindanix

Nintedanib is a small molecule, competitive, triple angiokinase inhibitor that targets multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). In addition to RTK inhibition, nintedanib also prevents the actions of the nRTKs Lck, Lyn, and Src. The inhibition of the Src pathway by nintedanib has been shown to reduce lung fibrosis.

Nindanix is indicated for the treatment of locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) adenocarcinoma type in combination with docetaxel for the treatment of adult patients after the failure of first-line chemotherapy.

Features